Medartis Holding AG (MED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medartis Holding AG (MED) has a cash flow conversion efficiency ratio of 0.088x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF24.17 Million ≈ $30.56 Million USD) by net assets (CHF275.87 Million ≈ $348.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MED days of operational coverage to measure how many days the company can operate on defensive assets alone.
Medartis Holding AG - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Medartis Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medartis Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medartis Holding AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sedlmayr Grund und Immobilien AG
F:SPB
|
N/A |
|
Jiangxi Huangshanghuang Group Food Co Ltd
SHE:002695
|
0.026x |
|
Jupiter Life Line Hospitals Limited
NSE:JLHL
|
-0.009x |
|
AMG Advanced Metallurgical Group NV
AS:AMG
|
-0.018x |
|
China Building Material
SHG:603060
|
0.043x |
|
Zhejiang Hailide New Material Co Ltd
SHE:002206
|
0.065x |
|
INVEX Controladora S.A.B. de C.V
MX:INVEXA
|
0.423x |
|
Karelia Tobacco Company Inc
AT:KARE
|
0.022x |
Annual Cash Flow Conversion Efficiency for Medartis Holding AG (2015–2025)
The table below shows the annual cash flow conversion efficiency of Medartis Holding AG from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Medartis Holding AG.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF275.87 Million ≈ $348.78 Million |
CHF34.82 Million ≈ $44.02 Million |
0.126x | +6.11% |
| 2024-12-31 | CHF269.65 Million ≈ $340.91 Million |
CHF32.07 Million ≈ $40.55 Million |
0.119x | +51.78% |
| 2023-12-31 | CHF254.96 Million ≈ $322.34 Million |
CHF19.98 Million ≈ $25.26 Million |
0.078x | +574.45% |
| 2022-12-31 | CHF237.78 Million ≈ $300.62 Million |
CHF-3.93 Million ≈ $-4.97 Million |
-0.017x | -117.66% |
| 2021-12-31 | CHF224.00 Million ≈ $283.19 Million |
CHF20.95 Million ≈ $26.49 Million |
0.094x | +58.02% |
| 2020-12-31 | CHF213.04 Million ≈ $269.33 Million |
CHF12.61 Million ≈ $15.94 Million |
0.059x | +57.27% |
| 2019-12-31 | CHF215.57 Million ≈ $272.54 Million |
CHF8.11 Million ≈ $10.26 Million |
0.038x | +27.36% |
| 2018-12-31 | CHF218.23 Million ≈ $275.91 Million |
CHF6.45 Million ≈ $8.15 Million |
0.030x | -95.43% |
| 2017-12-31 | CHF17.04 Million ≈ $21.54 Million |
CHF11.01 Million ≈ $13.92 Million |
0.646x | -7.16% |
| 2016-12-31 | CHF17.10 Million ≈ $21.62 Million |
CHF11.91 Million ≈ $15.06 Million |
0.696x | +375.23% |
| 2015-12-31 | CHF-46.95 Million ≈ $-59.36 Million |
CHF11.88 Million ≈ $15.02 Million |
-0.253x | -- |
About Medartis Holding AG
Medartis Holding AG, a medical device company, engages in the development, manufacturing, and sales of implant solutions worldwide. The company's medical devices are used for the treatment of surgical fixation of bone fractures for upper and lower extremities, as well as for the cranio-maxillofacial surgery. It provides products for the hand, wrist, forearm, elbow, shoulder, and foot and ankle, a… Read more